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1 Detailed Results 
Table S. 1: Predicted cases of disability 2015-2025. (95% uncertainty intervals) 
Year All persons Men Women 
2015 2,251,225 (2,234,794-2,267,986) 
922,198 
(911,016-932,855) 
1,329,147 
(1,316,237-1,342,710) 
2016 2,305,968 (2,288,503-2,323,692) 
951,815 
(939,714-963,034) 
1,354,398 
(1,340,333-1,368,847) 
2017 2,358,618 (2,340,071-2,379,518) 
981,131 
(968,316-993,900) 
1,377,602 
(1,362,379-1,394,832) 
2018 2,413,948 (2,392,030-2,435,340) 
1,011,248 
(996,556-1,025,173) 
1,402,890 
(1,385,718-1,419,979) 
2019 2,470,933 (2,441,840-2,495,505) 
1,042,121 
(1,025,662-1,058,276) 
1,428,961 
(1,408,509-1,448,636) 
2020 2,526,136 (2,492,134-2,555,829) 
1,072,611 
(1,053,071-1,091,239) 
1,453,139 
(1,427,172-1,475,253) 
2021 2,579,557 (2,542,306-2,617,358) 
1,103,144 
(1,078,727-1,126,678) 
1,476,335 
(1,445,324-1,506,401) 
2022 2,633,744 (2,586,828-2,680,767) 
1,134,485 
(1,105,974-1,161,545) 
1,500,500 
(1,460,971-1,537,922) 
2023 2,693,231 (2,636,494-2,750,364) 
1,167,276 
(1,135,941-1,200,504) 
1,525,727 
(1,478,254-1,571,590) 
2024 2,753,674 (2,679,587-2,818,366) 
1,201,302 
(1,160,976-1,238,509) 
1,551,329 
(1,495,101-1,604,529) 
2025 2,811,053 (2,727,384-2,889,965) 
1,236,268 
(1,187,308-1,278,668) 
1,577,604 
(1,508,284-1,638,884) 
 
Table S. 2: Predicted crude prevalence of disability 2015-2025 (95% uncertainty intervals) 
Year All persons Men Women 
2015 21.7 (21.5 - 21.8) 19.6 (19.3 - 19.8) 23.4 (23.1 - 23.6) 
2016 21.8 (21.6 – 22.0) 19.8 (19.5  20.0) 23.5 (23.2 - 23.7) 
2017 21.9 (21.7 - 22.1) 20.0 (19.7 - 20.2) 23.6 (23.3 - 23.8) 
2018 22.0 (21.9 - 22.2) 20.1 (19.9 - 20.4) 23.6 (23.4 - 23.9) 
2019 22.2 (22.0 - 22.4) 20.3 (20.1 - 20.6) 23.7 (23.5 -24.0) 
2020 22.3 (22.1 - 22.5) 20.5 (20.2 - 20.8) 23.8 (23.5 - 24.1) 
2021 22.4 (22.2 - 22.6) 20.7 (20.4- 21.0) 23.9 (23.6 - 24.2) 
2022 22.5 (22.2 - 22.8) 20.8 (20.5 - 21.2) 23.9 (23.5 - 24.3) 
2023 22.6 (22.3 - 22.9) 21.0 (20.6 - 21.3) 24.0 (23.5 - 24.4) 
2024 22.6 (22.3 - 22.9) 21.1 (20.7 - 21.5) 24.0 (23.5 - 24.5) 
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2025 22.7 (22.3 - 23) 21.2 (20.7 - 21.6) 24.0 (23.4 - 24.5) 
 
Our model predicts that the age-standardised prevalence of disability in the population aged over 65 
will remain broadly constant to 2025 in both men and women. However, differing trends are revealed 
when looking at disease-related disability states. The age-standardised prevalence of CVD-related 
disability will decrease in men and women between 2015 and 2025, following the declines in CVD 
incidence and mortality (see red line in panel B of Figure S. 1 and Figure S. 2, included below). In 
contrast, the age-standardised prevalence of dementia-related disability and other disease-related 
disability will both increase between 2015 and 2025. 
 
Figure S. 1: Projected number of cases (A) and age-standardised prevalence (B) of disease-related 
disability in men aged≥65 years from 2015 to 2025 in England and Wales. 
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Figure S. 2: Projected number of cases (A) and age-standardised prevalence (B) of disease-related 
disability in women aged≥65 years from 2015 to 2025 in England and Wales. 
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2  Sensitivity analysis 
We assumed, as observed in ELSA, that the trend in CVD incidence would mirror the rate of decline 
of CVD mortality. We also assumed that dementia incidence would follow a 2.7% annual decline 
based on analysis of the incidence trends across ELSA waves (2002-2013).1 
Due to the conflicting evidence on trends in dementia we examined two alternative assumptions on its 
future trend: a constant trend (no annual decline) over the time horizon (scenario 1) and, an annual 
decline of 4% in dementia incidence (scenario 2). 
Table S.3 provides estimates of total numbers of people with disability in 2025 according to different 
assumptions about the annual trends in dementia incidence. Totals remain almost unchanged despite 
different calendar trends in incidence of dementia. However, the two alternative assumptions 
regarding the trend in future dementia incidence do affect the numbers in the disease-related disability 
states (see Figure S. 3 to Figure S. 6).  If dementia incidence remains unchanged over the next decade, 
the burden of dementia-related disability will increase compared to our main prediction (see dotted 
green lines in Figure S. 5). This increase will be counter-balanced by a decrease in the number of 
cases of other types of disability, including CVD-related disability (see dotted green lines in Figure S. 
4 and Figure S. 6).  
Conversely, a faster annual decline in dementia incidence of 4% would result in fewer cases of 
dementia-related disability (see dashed blue lines in Figure S. 5) but an increase in the numbers of 
other types of disability (see dashed blue lines in Figure S. 4 and Figure S. 6). 
Table S. 4 display the estimates of healthy life expectancies at 65 in 2025 under two alternative 
assumptions on annual trends in dementia incidence.  Notice that the proportion of life expectancy 
lived with disability will remain virtually unchanged from the baseline scenario for both men and 
woman   
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Table S. 3 Comparison of the numbers of disability cases (thousands) in 2025 under alternative 
assumptions on annual trends in dementia incidence. (95% uncertainty intervals) 
 Annual trend in dementia incidence 
 2.7% annual 
decline (baseline) 
No annual decline 4% annual decline 
 Disability cases  
2025 
Disability cases  
2025 
Difference 
from 
Baseline 
Disability cases  
2025 
Difference 
from 
Baseline 
All 2,811 (2,727-2,890) 2,923 (2,834-3,007) 111.5 2,803 (2,721-2,881) -8 
Men 1,236 (1,187-1,279) 1,283 (1,231-1,329) 47.2 1,232 (1,183-1,273) -4.6 
Women 1,578 (1,508-1,639) 1,641 (1,567-1,707) 63.7 1,574 (1,506-1,634) -3.5 
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Figure S. 3: Predicted cases and standardised prevalence of CVD and dementia-related disability 2015-
2025 
 
Figure S. 4: Predicted cases and standardised prevalence of CVD-related disability 2015-2025 
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Figure S. 5: Predicted cases and standardised prevalence of dementia-related disability 2015-2025 
 
Figure S. 6: Predicted cases and standardised prevalence of Non-CVD/ Non-dementia related disability 
2015-2025 
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Table S. 4: Comparison of the life expectancies at 65 in 2015 under alternative assumptions on annual 
trends in dementia incidence (95% uncertainty intervals) 
 Year 2015 2025 
 Annual trend 
in dementia 
incidence 
Baseline  
(2.7% annual 
decline) 
No annual 
decline 
Baseline  
(2.7% annual 
decline)  
4% annual 
decline 
Men      
 Life expectancy 
(LE) 
19.0 (18.7-
19.3) 
22.4 (20.5-
24.8) 
21.7 (19.9-
23.9) 
21.9 (20.0-
24.1) 
 Disability-free 
life expectancy 
(DFLE) 
14.9 (14.7-
15.1) 
16.9 (15.8-
18.1) 
16.5 (15.4-
17.6) 
16.7 (15.6-
17.8) 
 Disabled life 
expectancy 
(DLE) 
4.1 (3.9-4.2) 5.5 (4.7-6.7) 5.2 (4.4-6.3) 5.2 (4.4-6.3) 
 Proportion (%) 
DLE: LE 
21.4 (21.0-
21.7) 
24.6 (22.7-
27.0) 
24.0 (22.2-
26.4) 
23.8 (22.1-
26.2) 
Women      
 Life expectancy 
(LE) 
21.0 (20.8-
21.2) 
23.0 (20.4-
25.7) 
22.1 (19.7-
24.7) 
22.2 (19.8-
24.8) 
 Disability-free 
life expectancy 
(DFLE) 
15.8 (15.7-
15.9) 
16.9 (15.5-
18.3) 
16.4 (15.1-
17.7) 
16.5 (15.2-
17.8) 
 Disabled life 
expectancy 
(DLE) 
5.2 (5.1-5.3) 6.1 (4.9-7.6) 5.7 (4.6-7.1) 5.7 (4.7-7.1) 
 Proportion (%) 
DLE: LE 
24.9 (24.5-
25.2) 
26.4 (24.1-
29.5) 
25.8 (23.5-
28.9) 
25.7 (23.5-
28.8) 
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3 Research in context 
We reviewed existing evidence in October 2016, searching PubMed database for any studies 
forecasting future trends in disability or dementia or life expectancy in the UK. The search terms used 
were the following: 
("Dementia"[Mesh] OR "Disabled Persons"[Mesh] OR "Life Expectancy"[Mesh] OR Disab*[ti] 
OR Dementi*[ti] OR Longevit*[ti] OR Life expectan*[ti])  
AND  
("Computer Simulation"[Mesh] OR "Forecasting"[Mesh] OR "Population Forecast"[Mesh] OR 
Simulation*[ti] OR Model*[ti] OR forecast*[ti])  
AND  
("Great Britain"[MeSH Terms] OR United Kingdom[Text Word] OR "England"[ti] OR 
"Wales"[ti] OR "Scotland"[ti] OR "UK"[ti] OR "United Kingdom"[ti] OR "Britain"[ti])  
Papers which were not relevant were manually removed. We performed additional searches using 
lists of references retrieved from relevant papers. The results of the search can be found in Table S. 5  
Table S. 5: Results of the systematic review 
Authors Title Population Methods Outcomes Competing 
risks 
Time 
Horizon
Jagger et 
al2 
The effect of dementia 
trends and treatments 
on longevity and 
disability: a simulation 
model based on the 
MRC Cognitive 
Function and Ageing 
Study (MRC CFAS). 
England Dynamic macro-
simulation 
Dementia 
and 
disability 
prevalence 
Conditional 
Transition 
probabilities 
(conditional 
on specific 
morbidities 
such as 
CVD) 
2006-
2026 
Bennett 
et al3 
The future of life 
expectancy and life 
expectancy inequalities 
in England and Wales: 
Bayesian 
spatiotemporal 
forecasting. 
England and 
Wales 
Bayesian 
spatiotemporal 
model 
Life 
expectancy  
at a local, 
small area 
levels 
No 
2012-
2030 
Office 
for 
National 
Statistics
4 
Past and projected data 
from the period and 
cohort life tables: 
2014-based, UK, 1981 
to 2064, Office for 
National Statistics 
(2015) 
 
United 
Kingdom 
Mortality 
projections 
Life 
expectancy 
No 
1981-
2064 
13 
 
Comas-
Herrera 
et al5 
Cognitive impairment 
in older people: future 
demand for long-term 
care services and the 
associated costs 
England Macrosimulation Dementia 
and 
disability 
No 
2002 
and 
2031 
4 Overview of IMPACT Better Aging Model 
The IMPACT Better Ageing Model (IMPACT-BAM) is a discrete-time Markov model which follows 
the progression of a healthy population (aged 35+ years old) from England and Wales into ten 
different health states characterised by the presence or absence of cardiovascular disease (CVD), 
cognitive impairment and functional impairment from 2006 to 2025. The model structure is presented 
in Figure S. 7, the health states are described in Table S. 6 and transition probabilities, pi,j, in Table S. 
7 
Prior to simulation, we populated each state in the model based on ONS population estimates in 2006 
(start year) and prevalence of the above conditions from ELSA, except for the new cohort of 35-year 
olds that enters the system through the disease-free state (see section 5.10). The simulation allows 
individuals to move to other states in the model. The arrows in Figure S. 7 indicate the possible 
movements of people between these ten states, which are governed by one-year probabilities of 
transition.  
For example, a healthy 55-year man starts the simulation in state 1 (Disease-free state) in 2006. He 
moves to state 2 (CVD) in 2007 after having a stroke. In 2008 he could either die from complications 
of the stroke (he moves to state 9), any other causes (he moves to state 10) or he could develop 
cognitive impairment (moving to state 3) or disability (moving to state 5). As above, movements to 
any state are driven by transition probabilities. Detailed information on the estimation of transition 
probabilities is provided in sections 5.2 to 5.9 
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Then, to calculate the number of people with disability in year t, we count the number of people in the 
states that represent disability (states 5, 6, 7 and 8) at year t. To calculate the number of individuals 
with dementia, we count the number of people in state 6 and 7 at year t, and do so similarly for other 
conditions. These numbers are then used to calculate the prevalence of any disease in the model. 
Detailed information on output calculation can be found in section 7. 
Figure S. 7: IMPACT-BAM model structure. Transitions to death states 9 and 10 are possible from any 
state.
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Table S. 6: Description of the health states 
Health state Name Description 
1 Disease-free 
population 
People free of cardiovascular disease (CVD), cognitive 
impairment (CI) or functional impairment (FI) 
2 CVD only Cardiovascular disease 
3 CVD and CIND Cardiovascular disease and cognitive impairment no dementia 
4 CIND Cognitive impairment no dementia 
5 CVD and FI Cardiovascular disease and functional impairment 
6 CVD, CIND and FI Cardiovascular disease and dementia (cognitive + functional 
impairment) 
7 DEMENTIA cognitive + functional impairment 
8 Other disease-related 
FI 
Functional impairment no related to CVD or/and Dementia  
9 CVD death Death from CVD causes 
10 Non-CVD death Death from a different cause than CVD 
 
Table S. 7: Description of transition probabilities. Each transition probability is stratified by sex and age 
1-year transition probability  From  To 
݌ଵ,ଵ Disease-free population Disease-free population 
݌ଵ,ଶ Disease-free population CVD only 
݌ଵ,ଷ Disease-free population CVD and CIND 
݌ଵ,ସ Disease-free population CIND 
݌ଵ,଼ Disease-free population Non-CVD/Non-dementia FI 
݌ଵ,ଽ Disease-free population CVD death 
݌ଵ,ଵ଴ Disease-free population Non-CVD death 
݌ଶ,ଶ CVD only CVD only 
݌ଶ,ଷ CVD only CVD and CIND 
݌ଶ,ହ CVD only CVD and FI 
݌ଶ,ଽ CVD only CVD death 
݌ଶ,ଵ଴ CVD only Non-CVD death 
݌ଷ,ଷ CVD and CIND CVD and CIND 
݌ଷ,଺ CVD and CIND CVD and Dementia 
݌ଷ,ଽ CVD and CIND CVD death 
݌ଷ,ଵ଴ CVD and CIND Non-CVD death 
݌ସ,ସ CIND CIND 
݌ସ,଻ CIND Dementia 
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݌ସ,ଽ CIND CVD death 
݌ସ,ଵ଴ CIND Non-CVD death 
݌ହ,ହ CVD and FI CVD and FI 
݌ହ,ଶ CVD and FI CVD only 
݌ହ,ଽ CVD and FI CVD death 
݌ହ,ଵ଴ CVD and FI Non-CVD death 
݌଺,଺ CVD and dementia CVD and dementia 
݌଺,ଷ CVD and dementia CVD and CIND 
݌଺,ଽ CVD and dementia CVD death 
݌଺,ଵ଴ CVD and dementia Non-CVD death 
݌଻,଻ Dementia Dementia 
݌଻,ସ Dementia CIND 
݌଻,ଽ Dementia CVD death 
݌଻,ଵ଴ Dementia Non-CVD death 
݌଼,ଵ Other disease-related FI Disease-Free population 
݌଼,ହ Other disease-related FI CVD and FI 
݌଼,଺ Other disease-related FI CVD and Dementia 
݌଼,଻ Other disease-related FI Dementia 
݌଼,଼ Other disease-related FI Non-CVD/Non-dementia FI 
݌଼,ଽ Other disease-related FI CVD death 
݌଼,ଵ଴ Other disease-related FI Non-CVD death 
5 Inputs and Calculations 
5.1 Case definitions 
Cardiovascular disease (represented in the model by states 2,3,5 and 6 in Figure S.7) was defined as 
having a diagnosis of cardiovascular disease, myocardial infarction, stroke and/or angina; equivalent 
to the ICD10 codes I00-I99, G45, Q200-Q289, M300-M319, D180-D189, A182, K550-K559, R00-
R009, R071-R074, R098, R230, R590-R599 and R943. 
Cognitive impairment no dementia (states 3 and 4) was defined as impairment in two or more 
domains of cognitive function (such as orientation to time, immediate and delayed memory, verbal 
fluency, and numeracy function), or a score higher than 3.6 on the Informant Questionnaire for 
Cognitive Decline (IQCODE)10 administered for subjects who were unable to participate in the 
study.6 
Functional impairment (states, 5, 6, 7 and 8)was defined as the inability to independently perform one 
or more activities of daily living (ADL). The ADLs included getting in or out of bed, walking across a 
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room, bathing or showering, using the toilet, dressing, cutting food and eating. We distinguished four 
disability states: state 5 defined as CVD-related disability, state 7 as dementia-related disability, state 
6 as CVD and dementia related disability and state 8 as other disease-related disability defined as 
other forms of disability not linked to CVD or dementia. To quantify the burden of CVD- related 
disability, we did not consider the contributions of state 6 (CVD and dementia related disability) as 
we wanted to isolate the disability burden associated to CVD only. Similarly for dementia-related 
disability. 
Dementia (states 6 and 7) was defined based on the co-existence of cognitive impairment and 
functional impairment or a report of a doctor diagnosis of dementia by the participant or carer. 
5.2 Incidence of CVD (P1, 2; P4, 3, P8,5) 
Denote ܲሺܥܸܦሻ	to be the incidence of CVD. To calculate CVD incidence, ܲሺܥܸܦሻ,		we obtained 2-
year incidence rates from the English Longitudinal Study of Ageing (ELSA) and fitted a logistic 
regression model of the form: 
݈݋݃݅ݐ	݅݊ܿ݅݀݁݊ܿ݁ ൌ ߚ଴ ൅ ߚ௔௚௘ܽ݃݁ଷହ ൅ ߚ௦௘௫ݏ݁ݔ ൅ ߚሺݏ݁ݔ ∗ ܽ݃݁ଷହሻ+	ߚ௦௧௔௧௘ݏݐܽݐ݁    
Where ܽ݃݁ଷହis individual age centred at 35 and state are those states (states 1, 4 and 8) from where 
transitions to CVD states (states 2, 3 and 5) are allowed. 
From the logistic regression estimates, 2-year transition probabilities were computed which were later 
transformed into gender specific 1-year transition probabilities for single years of age. 
In our model, we defined states 2 and 4 (CVD-only and CIND-only) as mutually exclusive (i.e. a 
patient who is in the CVD-only state does not have CIND at the same time and vice versa). Therefore, 
to calculate the	transition	probability	݌ଵ,ଶ	we	subtract	the	proportion	of	patients	who	have	both	
CVD	and	CIND,	݌ଵ,ଷ	
݌ଵ,ଶ ൌ ܲሺܥܸܦሻ െ ݌ଵ,ଷ  
5.3 Incidence of CIND (P1, 4; P2, 3, P8,7) 
Denote ܲሺܥܫܰܦሻ	to be the incidence of “cognitive impairment no dementia”. To calculate CIND 
incidence, ܲሺܥܫܰܦሻ,	2-year incidence rates from ELSA were modelled as follows: 
We fitted a logistic regression model of the form: 
݈݋݃݅ݐ	݅݊ܿ݅݀݁݊ܿ݁ ൌ ߚ଴ ൅ ߚ௔௚௘ܽ݃݁ହ଴ ൅ ߚ௦௘௫ݏ݁ݔ ൅ ߚሺݏ݁ݔ ∗ ܽ݃݁ହ଴ሻ ൅ ߚ൫ݏ݁ݔ ∗ ܽ݃݁ହ଴ଶ ൯ ൅ ߚ௦௧௔௧௘ݏݐܽݐ݁
     
Where ܽ݃݁ହ଴is individual age centred at 50 and state are those states (states 1, 2 and 8) from where 
transitions to CI  states (states 4, 3 and 7) are allowed. 
This allowed us to compute 2-year transition probabilities that were later transformed into gender 
specific 1-year transition probabilities for single years of age. The incidence rates from ELSA are 
likely to be underestimated due to higher drop out of those who do develop cognitive impairment. 
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In our model, we defined states 2 and 4 (CVD-only and CIND-only) as mutually exclusive (i.e. a 
patient who is in the CVD-only state does not have CIND at the same time and vice versa). Therefore, 
to calculate the transition probability 	݌ଵ,ସ	, we subtract the proportion of patients who have both CVD 
and CIND, ݌ଵ,ଷ	
݌ଵ,ସ ൌ ܲሺܥܫܰܦሻ െ ݌ଵ,ଷ   
  
5.4 Incidence of CVD and CIND (P1, 3; P8,6) 
We assume that CVD and CIND are independent events. Therefore, (݌ଵ,ଷ ൌ ܲሺܥܸܦ	 ∩ ܥܫܰܦሻሻ	from 
a healthy state, ݌ଵ,ଷ ൌ ܲሺܥܸܦሻ ൈ ܲሺܥܫܰܦሻ from above formula. 
Similarly for ݌଼,଺ 
5.5 Incidence of functional impairment states (P1, 8; P2, 5; P3,6 and P4,7  ) 
We obtained the 2-year incidence rates for functional impairment ELSA and fitted logistic regression 
models of the form: 
݈݋݃݅ݐ	݅݊ܿ݅݀݁݊ܿ݁	ܨܫ ൌ ߚ଴൅ߚ௔௚௘ܽ݃݁ଷହ ൅ ߚ௦௘௫ݏ݁ݔ ൅ ൅ߚ௦௧௔௧௘ݏݐܽݐ݁ ൅ ߚሺݏ݁ݔ ∗ ܽ݃݁ଷହሻ ൅ ߚሺݏݐܽݐ݁ ∗
ܽ݃݁ଷହሻ         
Where ܽ݃݁ଷହis individual age centred at 35 and state are those states (states 1, 2, 3 and 4) from where 
transitions to FI states (states 8, 5, 6 and 7) are allowed.    
This allowed 2-year transition probabilities to be computed which were later transformed into gender 
specific1-year transition probabilities for single years of age. These transition probabilities do not 
have a calendar effect. 
5.6 Recovery from functional impairment states (P8, 1; P5, 2; P6,3 and P7,4) 
We obtained the 2-year incidence rates for functional impairment ELSA and fitted logistic regression 
models of the form: 
݈݋݃݅ݐ	݅݊ܿ݅݀݁݊ܿ݁	ܨܫ ൌ ߚ଴൅ߚ௔௚௘ܽ݃݁ଷହ ൅ ߚ௦௘௫ݏ݁ݔ ൅ ൅ߚ௦௧௔௧௘ݏݐܽݐ݁ ൅ ߚሺݏ݁ݔ ∗ ܽ݃݁ଷହሻ ൅ ߚሺݏݐܽݐ݁ ∗
ܽ݃݁ଷହሻ         
Where ܽ݃݁ଷହis individual age centred at 35 and state are those FI states (states 8, 5, 6 and 7) from 
where transitions to states without FI (states 1, 2, 3 and 4) are allowed.    
This allowed 2-year transition probabilities to be computed which were later transformed into gender 
specific1-year transition probabilities for single years of age. These transition probabilities do not 
have a calendar effect. 
5.7 Transition probabilities from state i to the death states (Pi, 9 and Pi, 10) 
The computation of the transition probabilities 	݌௜,ଽ	involved three steps: 
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For the first step, CVD mortality probabilities of CVD up 2025 in 5-year age bands were calculated 
using the Bayesian Age Period Cohort (BAPC) model,7 with ONS mortality and population estimates 
from 1982-2012 for England and Wales as inputs. 
The curve fitting tool in MATLAB was then used to obtain CVD mortality probabilities for single 
years of age, starting at 35 years old. The probabilities are estimated using piecewise cubic Hermit 
interpolation to estimate values that lie between known data points, with the monotonicity and the 
shape of the data preserved. We denote these probabilities of death by 	݉_ܿݒ݀௔,௧, where, a is the age 
of individual and t the calendar year.  
For the second step, we calculated mortality rates from ELSA for the age groups 50-59, 60-69, 70-79 
and 80-89 and fitted two logistic regression models of the form: 
 ݈݋݃݅ݐ	ܿݒ݀_݀݁ܽݐ݄ ൌ ߚ଴ ൅ ߚ௔௚௘ܽ݃݁ଷହ ൅ ߚ௠௔௟௘݈݉ܽ݁ ൅ ߚሺ݈݉ܽ݁ ∗ ܽ݃݁ଷହሻ   
 ݈݋݃݅ݐ	ܿݒ݀_݀݁ܽݐ݄ ൌ ߚ଴ ൅ ߚ௔௚௘ܽ݃݁ଷହ ൅ ߚ௠௔௟௘݈݉ܽ݁ ൅ ߚሺ݈݉ܽ݁ ∗ ܽ݃݁ଷହሻ+	઺ܛܛܜ܉ܜ܍   
Where ܽ݃݁ଷହis individual age centred at 35, ઺ܛ is a vector containing the β coefficients for all the 
states. 
The first equation allowed us to compute gender specific baseline transition probabilities for single 
years of age. We defined these as ݌෤଴,ଽ,௔ 
The second equation allowed us to compute gender and state-specific transition probabilities for 
single years of age. We defined these as ݌෤௜,ଽ,௔ 
To estimate how different the state-specific transition probabilities are from the baseline transition 
probabilities we calculated	ܿݒ݀௔,௜ ൌ ௣෤೔,వ,ೌ௣෤బ,వ,ೌ. 
The probabilities of death, 	݉_ܿݒ݀௔,௧,  are the probabilities of dying (from CVD) regardless of the 
state an individual is coming from, similar to the baseline transition probabilities ݌෤଴,ଽ,௔	from the 
ELSA study. The 	݉_ܿݒ݀௔,௧ are calculated using the entire England and Wales population and allow 
for cohort and calendar effects and are preferred over the ݌෤଴,ଽ,௔.  
To allow for each subject’s initial state, the 	݉_ܿݒ݀௔,௧ were multiplied by the factor ܿݒ݀௔,௜ to obtain 
the age, gender and state-specific transition probabilities	݌௜,ଽ,௔. 
Transition probabilities 	݌௜,ଵ଴,௔	were calculated in the same manner. 
5.8 Calendar effect for CVD and CIND incidence 
Let		∆௔,௧ାଵൌ ௠_௖௩ௗೌ,೟శభ௠_௖௩ௗೌ,೟  where ݉_ܿݒ݀௔,௧ is the age-specific probability of death from CVD causes in 
year t.  Therefore, 	∆௔,௧ାଵ	is an age-specific adjustment factor describing how different the probability 
of CVD death in year t+1 is from the probability of CVD death in the previous year t.  
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We assume that annual changes in CVD incidence mirror the annual changes in CVD mortality as 
observed in ELSA (See Figure S. 8). In other words, we assume the annual percentage change in 
CVD incidence equals to the annual percentage change in CVD mortality. Therefore, to obtain the 
incidence of CVD allowing for a calendar effect, we multiplied 	ܲሺܥܸܦሻ௔,௧ାଵ	by	൫	∆௔,௧ାଵ൯	.  
Likewise, we assume that these annual changes in CVD incidence would also affect	݌଼,ହ, thus the 
same calendar was applied. 
However, the incidence of CIND, 	ܲሺܥܫܰܦሻ௔,௧ାଵ,	is assumed to decrease by 2.7% per calendar year, 
ie, 	ܲሺܥܫܰܦሻ௔,௧ାଵ = 0.973 * 	ܲሺܥܫܰܦሻ௔,௧. 
The above annual decline for CIND was estimated with data collected over 6 waves of ELSA (2002-
2013) and using an elaborate model that takes into account losses to follow-up and mortality. The 
results of these analyses suggested that the calendar trend per year is -2.7% (95% confidence interval -
2.9, -2.4).8  
Likewise, we assume an annual 2.7% decrease for 	݌଼,଺ and 	݌଼,଻.The calculations of ݌ଵ,ଶ, ݌ଵ,ଷ and 
݌ଵ,ସ, proceed as previously described.  
Figure S. 8: Age and sex standardised cardiovascular incidence and mortality rates in the English 
Longitudinal Study of Ageing 2002-2013 
 
5.9 Recurrent state transition probabilities 
The recurrent state transition probabilities such as p1,1, p2,2, p3,3, etc. were calculated using the 
following formula: 
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 ݌௜,௜ ൌ 1 െ ∑ ݌௜,௝௃௝ୀଵ , where J is a vector containing the states (other than i itself) to where a transition 
from state i is possible. 
5.10 Prevalence of initial states 
We obtained the 2-year prevalence rates for states 2, 3, 4, 5, 6, 7 and 8 from ELSA for 5-year age 
groups. Due to the small number, it was assumed that those aged <50 have a prevalence probability of 
cognitive impairment equal to zero. This was done by dividing the number of people in each state by 
the total number of individuals in that age-sex strata in the pooled ELSA data and attributed to 2006 
which is the mid-point of the ELSA data collection period (2002-2013). 
We then used the curve fitting tool in MATLAB to obtain data for single year of age starting at 35 
years old. 
ELSA contains information on 142 individuals aged 35 to 39. Approximately 97% of these 
individuals were free of CVD, cognitive impairment, dementia and disability. Therefore, we assumed 
that the new cohort of 35s entering the model at each year is free of disease. This assumption has no 
effect on the outputs reported in the manuscript, as the 35-year-olds entering the model in 2006 
(beginning of the simulation) will be 54 years old by 2025, while the outputs reported in this study are 
for those 65 and older.  
6 Matrix calculations 
The following table contains the steps to calculate the Markov model 
Table S. 8: Matrix notation for programming purposes mainly. (Example for men) 
Matrix formulation (Example for men) Description 
ܘ_ܕ܉ ൌ ൣp_mୟ,ଵ, p_mୟ,ଶ, … , p_mୟ,ଵ଴ ൧ Column vector containing prevalence rates for all 
states for men aged a 
ܯ௔,଴ Scalar containing initial population men aged a 
Tmୟ,୲ ൌ ൥
݌ଵ,ଵ,௔,௧ ⋯ ݌ଵ,ଵ଴,௔,௧
⋮ ⋱ ⋮
݌ଵ଴,ଵ,௔,௧ ⋯ ݌ଵ଴,ଵ଴,௔,௧
൩ 
Matrix for men aged a, containing the transition 
probabilities 
ܕ܉,ܜ ൌ ൣmୟ,୲,ଵ,mୟ,୲,ଶ, … ,mୟ,୲,ଵ଴	൧ Column vector containing the number of men aged 
a in each state at time t 
For ݐ ൌ 0 
 
ܕ܉,૙ ൌ ܯ௔,଴ ∙ ܘ_ܕ܉ 
For ݐ ൌ ݊ 
ܕ܉,ܜ ൌ ܕ܉ି૚,ܜି૚ ∙ ሾTୟିଵሿ୘ 
ܕ܉,ܜ ൌ ൦
݉௔ିଵ,௧ିଵ݌ଵ,ଵ,௔ିଵ,௧ିଵ ൅ ݉௔ିଵିଵ,௧ିଵ݌ଶ,ଵ,௔ିଵ,௧ିଵ ൅ ⋯൅݉௔ିଵ,௧ିଵ݌ଵ଴,ଵ,௔ିଵ,௧ିଵ,
݉௔ିଵ,௧ିଵ݌ଵ,ଶ,௔ିଵ,௧ିଵ ൅ ݉௔ିଵ,௧ିଵ݌ଶ,ଶ,௔ିଵ,௧ିଵ ൅ ⋯൅݉௔ିଵ,௧ିଵ݌ଵ଴,ଶ,௔ିଵ,௧ିଵ,… ,
݉௔ିଵ,௧ିଵ݌ଵ,ଵ଴,௔ିଵ,௧ିଵ ൅ ݉௔ିଵ,௧ିଵ݌ଶ,ଵ଴,௔ିଵ,௧ିଵ ൅ ⋯൅݉௔ିଵ,௧ିଵ݌ଵ଴,ଵ଴,௔ିଵ,௧ିଵ
൪ 
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7 Output statistics from IMPACT-BAM 
The statistics generated from the IMPACT-BAM are summarised in Table S.9 
Table S. 9: Description of the main output variables. (Example for men) 
Output variable 
(Example for men) 
Description Equations 
݀_݉௔,௧ Number of male deaths aged a at 
the beginning of the cycle t 
݉௔,௧,ଽ ൅ ݉௔,௧,ଵ଴ 
݀݅ݏ_݉௔,௧ Number of men with disability 
aged a at the beginning of the 
cycle t 
݉௔,௧,ହ ൅ ݉௔,௧,଺ ൅ ݉௔,௧,଻+݉௔,௧,଼ 
ܿݒ݀_݉௔,௧ Number of men with CVD aged a 
at the beginning of the cycle t 
݉௔,௧,ଶ ൅ ݉௔,௧,ଷ ൅ ݉௔,௧,ହ ൅ ݉௔,௧,଺ 
ܿ݅_݉௔,௧ Number of men with cognitive 
impairment aged a at the 
beginning of the cycle t 
݉௔,௧,ଷ ൅ ݉௔,௧,ସ ൅ ݉௔,௧,଺ ൅ ݉௔,௧,଻ 
݀݁݉݁_݉௔,௧ Number of male deaths aged a at 
the beginning of the cycle t 
݉௔,௧,଺ ൅ ݉௔,௧,଻ 
ܧ_݉௔,௧ Life expectancy for men at age a 
at cycle t. Using Sullivan method5 
ݏ_݉௔,௧ ൌ ݉௔,௧,ଵ ൅ ݉௔,௧,ଶ ൅ ݉௔,௧,ଷ ൅ ݉௔,௧,ସ
൅ ݉௔,௧,ହ ൅ ݉௔,௧,଺ ൅ ݉௔,௧,଻
൅ ݉௔,௧,଼ 
ܲܮܻ_݉௔,௧ ൌ ݏ_݉௔,௧ ൅ ݏ_݉௔ାଵ,௧2  
ܶ݋ݐ݈ܽ	ܲܮܻ_݉௔,௧ ൌ ෍ܲܮܻ_݉௔,௧
஺
௔ୀ௔
 
ܧ_݉௔,௧ ൌ ܶ݋ݐ݈ܽ	ܲܮܻ_݉௔,௧ݏ_݉௔,௧  
ܦܮܧ_݉௔ Disabled life expectancy for men 
at age a. Using Sullivan method5 ܦܲܮܻ_݉௔,௧ ൌ
݀݅ݏ_݉௔,௧ ൅ ݀݅ݏ_݉௔ାଵ,௧
2  
ܶ݋ݐ݈ܽ	ܦܲܮܻ_݉௔,௧ ൌ ෍ܦܨܲܮܻ_݉௔,௧
஺
௔ୀ௔
 
ܦܮܧ_݉௔,௧ ൌ ܶ݋ݐ݈ܽ	ܦܲܮܻ_݉௔,௧݀݅ݏ_݉௔,௧  
ܦܨܮܧ_݉௔ Disability-free life expectancy for 
men at age a. Using Sullivan 
method9 
݂݀ݏ_݉௔,௧ ൌ ݉௔,௧,ଵ ൅ ݉௔,௧,ଶ ൅ ݉௔,௧,ଷ ൅ ݉௔,௧,ସ 
ܦܨܲܮܻ_݉௔,௧ ൌ ݂݀ݏ_݉௔,௧ ൅ ݂݀ݏ_݉௔ାଵ,௧2  
ܶ݋ݐ݈ܽ	ܦܨܲܮܻ_݉௔,௧ ൌ ෍ܦܨܲܮܻ_݉௔,௧
஺
௔ୀ௔
 
ܦܨܮܧ_݉௔,௧ ൌ ܶ݋ݐ݈ܽ	ܦܨܲܮܻ_݉௔,௧݂݀ݏ_݉௔,௧  
ܯܨܮܧ_݉௔ Morbidity-free life expectancy for 
men at age a. Using Sullivan 
method9 
݂݀ݏ_݉௔,௧ ൌ ݉௔,௧,ଵ 
ܯܨܮܻ_݉௔,௧ ൌ ݉௔,௧,ଵ ൅ ݉௔ାଵ,௧,ଵ2  
ܶ݋ݐ݈ܽ ܯܨܲܮܻ_݉௔,௧ ൌ ෍ܯܨܲܮܻ_݉௔,௧
஺
௔ୀ௔
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  ௧,௔݉_ݏ݂݀௧,௔݉_ܻܮܲܨܯ	݈ܽݐ݋ܶ ൌ ௧,௔݉_ ሶܧܮܨܯ
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8 Probability sensitivity analysis: Monte Carlo simulation 
8.1 Basic Monte Carlo simulation 
 
Let us define ࣂ࢐࢓ as a vector containing age and calendar (when applicable) specific values for 
the input parameter j at iteration m.  
࣓࢏࢓ as a vector containing age and calendar specific values for the output i at iteration m 
۷࢓ is a matrix containing all the age and calendar-specific inputs used in our Markov model at 
iteration m. 
۷࢓ ൌ ߠଵ௠, ߠଶ௠,… , ߠ௃௠ 
۽࢓ is a matrix containing all the age and calendar-specific outputs used in our Markov model at 
iteration m. 
۽࢓ ൌ ߱ଵ௠,߱ଶ௠,… ,߱ூ௠ 
For 1 to M: 
1. We sample ߠ௝	from the appropriate probability distribution described in Table S. 10 
2.  We use the matrix ۷࢓	to calculate a matrix outputs ۽࢓	using IMPACT-BAM 
 Summarise outputs in O: mean, median, 5th and 95th percentiles of the distribution as 
uncertainty intervals. 
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Table S. 10: Probability sensitivity analysis 
Input parameters Type of distribution and functions  
 
Source  
 
Prevalence for any state (Beta distribution: cases, sample size minus 
cases) 
ELSA 
Incidence of CVD Normal distribution (ln(mean), SE) 
Ln(mean)=Log-scaled predicted probability 
from the logit model 
SE= standard error from the predicted 
probability 
STATA command “margins” was used 
after fitting the logistic model described 
in section 5.2 to calculate the mean 
predicted probability and its associated 
standard error 
Incidence of CIND Normal distribution (ln(mean), SE) 
Ln(mean)=Log-scaled predicted probability 
from the logit model 
SE= standard error from the predicted 
probability  
STATA command “margins” was used 
after fitting the logistic model described 
in section 5.3 to calculate the mean 
predicted probability and its associated 
standard error 
Transition probabilities 
from/to functional 
impairment 
Normal distribution (ln(mean), SE) 
Ln(mean)=Log-scaled predicted probability 
from the logit model 
SE= standard error from the predicted 
probability 
STATA command “margins” was used 
after fitting the logistic model described 
in sections 5.5 and 5.6 to calculate the 
mean predicted probability and its 
associated standard error 
Probabilities to death 
states 
Posterior distribution BAMP software provided samples from 
the posterior distribution of the age-
specific CVD and Non-CVD mortality 
rates 
 
The choice of beta and normal distributions for prevalence estimates and the incidence of CVD, 
CIND and transition probabilities from/to functional impairment is suggested by the ISPOR-SMDM 
Modelling Good Research Practices Task Working Group-6.10 The ISPOR-SMDM Modelling Good 
Research Practices describes recommendations for achieving transparency and validation developed 
by a task force appointed by the International Society for Pharmacoeconomics and Outcomes 
Research and the Society for Medical Decision Making.   
We used a Bayesian Age-Period-Cohort model to estimate projections of probabilities of death. The 
Bayesian approach allows us to estimate a posterior distribution for the probabilities of death from 
which probabilities of death were sampled. We did not incorporate uncertainty in the ONS population 
projections of the cohort of 35-year olds. These principal projections are based on assumptions 
regarding future levels of fertility, migration and mortality which might add uncertainty to our 
estimates. However, population projections have proved to be relatively robust to mortality 
assumptions, whereas fertility and migrant variant assumptions only affect the projected numbers of 
children and young adults and hence, the effect on our model outputs will be very small.  
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9  Prevalence of disability from ELSA 
Table S. 11: Percentage of the ELSA sample with disability 
 All persons Men Women 
Age 
group All 
With 
disability 
(%) 
All 
With 
disability 
(%) 
All 
With 
disability 
(%) 
35+ 65955 10468 (15.9) 29165 4459 (15.3) 36790 6009 (16.3) 
65+ 32368 7206 (22.3) 14572 2976 (20.4) 17796 4230 (23.8) 
35 - 39 142 4 (2.8) 30 1 (3.3) 112 3 (2.7) 
40 - 44 465 17 (3.7) 107 4 (3.7) 358 13 (3.6) 
45 - 49 1373 79 (5.8) 263 15 (5.7) 1110 64 (5.8) 
50 - 54 7773 603 (7.8) 3150 243 (7.7) 4623 360 (7.8) 
55 - 59 12321 1251 (10.2) 5633 570 (10.1) 6688 681 (10.2) 
60 - 64 11513 1308 (11.4) 5410 650 (12) 6103 658 (10.8) 
65 - 69 9836 1371 (13.9) 4690 649 (13.8) 5146 722 (14) 
70 - 74 8510 1569 (18.4) 3986 728 (18.3) 4524 841 (18.6) 
75 - 79 6540 1527 (23.3) 2941 647 (22) 3599 880 (24.5) 
80 - 84 4315 1327 (30.8) 1794 486 (27.1) 2521 841 (33.4) 
85 - 89 2277 904 (39.7) 876 317 (36.2) 1401 587 (41.9) 
90+ 890 508 (57.1) 285 149 (52.3) 605 359 (59.3) 
 
Table S. 12: Percentage of cases of disability in ELSA with additional CVD and/or cognitive impairment 
 All persons Men Women 
Age 
group 
Disability 
Cases 
With CVD 
and/or CI 
(%) 
Disability 
Cases 
With CVD 
and/or CI 
(%) 
Disability 
Cases 
With CVD 
and/or CI 
(%) 
35+ 10468 4712 (45) 4459 2154 (48.3) 6009 2558 (42.6) 
65+ 7206 3831 (53.2) 2976 1637 (55) 4230 2194 (51.9) 
35 - 39 4 0 (0) 1 0 (0) 3 0 (0) 
40 - 44 17 0 (0) 4 0 (0) 13 0 (0) 
45 - 49 79 11 (13.9) 15 4 (26.7) 64 7 (10.9) 
50 - 54 603 141 (23.4) 243 71 (29.2) 360 70 (19.4) 
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55 - 59 1251 343 (27.4) 570 209 (36.7) 681 134 (19.7) 
60 - 64 1308 386 (29.5) 650 233 (35.8) 658 153 (23.3) 
65 - 69 1371 528 (38.5) 649 265 (40.8) 722 263 (36.4) 
70 - 74 1569 699 (44.6) 728 354 (48.6) 841 345 (41) 
75 - 79 1527 796 (52.1) 647 369 (57) 880 427 (48.5) 
80 - 84 1327 812 (61.2) 486 320 (65.8) 841 492 (58.5) 
85 - 89 904 624 (69) 317 217 (68.5) 587 407 (69.3) 
90+ 508 372 (73.2) 149 112 (75.2) 359 260 (72.4) 
10 Validation of the model 
We validated key model outputs against empirical observations using a graphical approach and by 
checking whether our estimates fall within the reported 95% confidence intervals (when available).  
We carried out partially-dependent validation of our estimates of CVD and Non-CVD deaths with 
observed ONS mortality data reported for the period 2006-2012. It is defined partially-dependent 
validation as this source was used to build a part of the model, but it does not wholly determine the 
outcome to be validated.11 The model provided a good match to the ONS estimates of the number of 
CVD and Non-CVD deaths (Figure S. 9 and Figure S. 10). 
We carried out independent validation (i.e. no information from these sources was used to build the 
model) of our model estimates of prevalence of CVD, disability and dementia, and life expectancy at 
age 65. Our estimates of CVD in 2011 for men fall within the 95% confidence intervals reported by 
the HSE (Figure S. 11). However, our model estimates higher prevalence of CVD in women. Our 
estimates of disability prevalence in 2014 for women fall within the 95% confidence intervals 
reported by ELSA wave 7 (Figure S. 12), but our model estimates a slighthly lower prevalence of 
disability  in men. 
Our age-specific estimates of dementia prevalence in 2011 were akin to those reported in CFAS II for 
the same year (Figure S. 13).  All our estimates of our age-specific prevalence estimates fall within 
the 95% confidence interval reported by CFAS II, except men 80-84 and women 85-89, which were 
both outside by a very narrow margin. 
Our estimates of LE at 65 for the period 2006-2012 were close to those reported by the ONS and 
EHLEIS (see Table S. 13). We also compare our projections of life expectancy at 65 with ONS 
projections and two studies published in the Lancet (only years 2025 and 2030 were available for 
comparison).3,12 
All sources of comparison reported increases in life expectancy at 65 and all previous estimates lie 
within IMPACT-BAM’s 95% credible intervals (Table S.14). The small differences between these 
studies and our estimates may be explained by the methodology used to calculate mortality 
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projections. The ONS makes assumptions on future improvements of mortality based on expert 
judgment.13 Bennet et al. and Kontis et al. use demographic models that incorporate data on age and 
birth cohort in mortality trends. Our model uses further information on disease specific mortality 
projections,14 specifically the combined effects of cardiovascular disease, dementia, disability and 
mortality to predict life expectancy.  Our conservative estimates for women compared to other studies 
may be explained by the fact that our model predicts that more women than men will die due to 
causes related to their higher prevalence of dementia and functional limitations. Among men, our 
estimates of life expectancy in men are sensitive to the declining trends in CVD incidence and 
mortality observed in ELSA over the past decade and projected forward in our model.  
In this section, comparisons should be made cautiously as the methodologies and underlying 
assumptions from the other sources are not directly comparable with ours. 
10.1 CVD mortality 
Figure S. 9: Predicted CVD mortality against ONS estimates 2006-2012 
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10.2 Non-CVD mortality 
Figure S. 10: Predicted Non-CVD mortality against ONS estimates 2006-2012 
 
 
10.3 Prevalence of CVD 
 
Figure S. 11: Predicted prevalence of CVD against Health Survey for England estimates in 2011. The 
error bars represent 95% uncertainty intervals for IMPACT-BAM predictions and 95% confidence 
intervals for HSE estimates. 
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10.4 Prevalence of disability 
Figure S. 12: Predicted prevalence of disability against wave 7 of ELSA. The error bars represent 95% 
uncertainty intervals for IMPACT-BAM predictions and 95% confidence intervals for ELSA estimates 
 
10.5 Prevalence of dementia 
Figure S. 13: Age and gender specific predicted prevalence of dementia against CFAS estimates in 20111. 
The error bars represent 95% uncertainty intervals for IMPACT-BAM predictions and 95% confidence 
intervals for CFAS II estimates. 
 
10.6 Life expectancy 
Table S. 13: Comparison of LE at 65 in our model against ONS and EHLEIS estimates 2006-2012 
  2006 2007 2008 2009 2010 2011 2012 
Men IMPACT-BAM 
for England and 
16.6  16.9 17.1 17.2 17.6 17.8 18.1 
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Wales 
ONS estimates 
for England and 
Wales 
17.3 17.5 17.6 17.9 18.1 18.4 18.4 
EHLEIS for 
UK1 17.3 17.5 17.6 18.0 18.2 18.5 18.5 
         
Women IMPACT-BAM 
for England and 
Wales 
19.2 19.6 19.8 19.9 20.4 20.5 20.8 
ONS estimates 
for England and 
Wales 
20.1 20.2 20.2 20.7 20.7 21.0 20.9 
EHLEIS for 
UK1 20.1 20.2 20.2 20.7 20.8 21.1 20.9 
1 EHLEIS only reports figures for the United Kingdom. However, their estimates are also very close to 
those reported by the ONS for England and Wales 
Table S. 14: Comparison of LE at 65 in our model against published projected for 2025 and 2030. ** 95% 
credible intervals in parenthesis. ++ Although no reported in this study, our model can produce estimates 
for 2030. #these estimates are an approximation since the data was presented in graphical format only. 
 Men Women 
 2025 2030 2025 2030 
IMPACT-BAM for 
England and Wales++ 
21.7 (19.9-23.9) 22.8 (19.6-27.3) 22.1 (19.7-24.7) 22.3 (18.8-27.6) 
ONS for England and 
Wales  
21.1 21.7 23.4 24.1 
Bennet et al (2015) for 
England and Wales# 
22.0 23.2 24.1 24.9 
Kontis et al (2017) for 
UK 
NA 20.9 (17.2-23.0) NA 22.7 (18.8-24.7) 
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